Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A large Swedish cohort study assesses whether glucagon-like peptide-1 receptor agonists increase the risk of anterior ischemic optic neuropathy in type 2 diabetes. Although a borderline elevated relative risk was observed, absolute incidenc
A nationwide cohort study reveals that two-thirds of patients with primary hyperparathyroidism exhibit end-organ damage at diagnosis or during follow-up, yet few receive parathyroidectomy, underscoring missed opportunities to reduce morbidi
This mediation analysis of a phase 2 MASH trial reveals that survodutide improves liver inflammation and fibrosis predominantly through weight-independent mechanisms, highlighting a potential direct hepatic effect beyond weight reduction.
This study reveals that Asian Indians with prediabetes or type 2 diabetes show significantly higher liver and abdominal fat despite similar BMI, highlighting liver fat’s key role in dysglycaemia and the importance of early interventio
A phase 3 trial demonstrates that once-weekly somapacitan is non-inferior to daily growth hormone injections in promoting linear growth in girls with Turner syndrome, offering a promising alternative with comparable safety and efficacy prof
Melatonin impairs glucose tolerance and early insulin secretion, particularly in carriers of the MTNR1B diabetes risk allele, revealing critical mechanisms linking melatonin signaling to diabetes susceptibility and highlighting the need for
A large study in veterans with type 2 diabetes found that adding GLP-1 receptor agonists to basal insulin did not improve insulin discontinuation rates compared to SGLT-2 inhibitors or DPP-4 inhibitors over three years.
This article examines factors influencing the one-year success rate of DMEK in treating corneal endothelial dysfunction, highlighting the impact of operative complications and donor-recipient variables based on findings from the Diabetes En
A large-scale proteomic study identified distinct MASLD subtypes influenced by sex differences and developed a four-protein score predicting all-cause mortality, advancing personalized risk assessment beyond traditional liver-centric models
This retrospective study assesses the efficacy and safety of pemetrexed, alone or combined with carboplatin, as salvage therapy for advanced thyroid cancer, showing promising response rates comparable to current second-line treatments.
This study demonstrates that dapagliflozin does not impair LDL catabolism but favorably shifts VLDL1 and VLDL2 catabolism toward normal physiology in type 2 diabetes, potentially contributing to reduced atherosclerosis risk.
A 2022 nationwide study shows insulin pump therapy in adults with type 1 diabetes is associated with significantly lower 30-day readmissions and reduced in-hospital mortality compared to injectable insulin alone.
Common bedside tests for peripheral arterial disease in diabetic patients show poor sensitivity, challenging their clinical reliability compared to advanced imaging modalities.
A nationwide cohort study found that SGLT2 inhibitor initiation was associated with a 27% lower risk of incident lung cancer in patients with COPD and type 2 diabetes compared with sulfonylureas.
A randomized trial found that levothyroxine treatment for subclinical hypothyroidism or hypothyroxinemia starting between 8 and 20 weeks of gestation did not improve IQ scores in children at age 5 years compared with placebo.
Long-term exposure to particulate matter and lack of green space were associated with increased risk of prediabetes, especially impaired glucose tolerance phenotypes, and reduced remission of isolated impaired fasting glucose.
In a prospective cohort study using multiple 24-hour urine collections, higher sodium excretion was associated with a 32% increased type 2 diabetes risk per 1,000 mg/day; potassium excretion showed no significant association.
A meta-analysis of 23 observational studies shows higher MIND diet adherence is associated with a 55% lower cancer risk and reduced all-cause and CVD mortality. Separately, the MIND trial now provides genetic data to explore precision nutrition for cognitive decline.
A metabolomic clock based on plasma metabolites accurately estimated chronological age (r=0.92) and was associated with mortality, frailty, and cognitive impairment across two European cohorts.
A cohort of 432 children with Graves disease found 24% developed neutropenia on methimazole, mostly within the first month. TPOAb-negative status and younger age increased risk.
Open language-specific specialty feeds and department pages.